Bioprocess Technology Market is expected to display a steady growth of 10.8% due to the rise in the incidence of infectious diseases | UnivDatos Market Insights – Yahoo Finance

NOIDA, India, Nov. 23, 2022 /PRNewswire/ — According to a new report published by UnivDatos Markets Insights, the Bioprocess Technology Market was valued at more than USD 17.5 Billion in 2020 and is expected to grow at a CAGR of around 10.8% from 2022-2028. The analysis has been segmented into Type (Consumables & Accessories, and Instruments); Application Type (Biopharmaceuticals, Specialty Products & Industrial Chemicals, and Environmental Management Aid); End User (Hospitals, Research Centers, and Research / Academic Institutes); Region/Country.
Click here to view the Report Description & TOC
https://univdatos.com/report/bioprocess-technology-market/
The Bioprocess Technology Market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the Bioprocess Technology Market. The Bioprocess Technology Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Bioprocess Technology Market at the global and regional levels.
Request for Sample Pages
https://univdatos.com/get-a-free-sample-form-php/?product_id=28108
Market Overview
Bioprocess technology is essential for the development of specialized chemicals, reagents, and biotherapeutics mainly by fusing the entirety of living matter or its constituent parts with nutrients. The procedures are the foundation for turning life science findings into practical industrial products. Substrates & media, biocatalysts, volume production, downstream processing, purification, and final processing are a few of the stages connected to bioprocess technology. In recent years, the adoption of bioprocess technology-related instruments has risen dramatically due to the rising incidences of infectious diseases and the increase in investments in the market. Furthermore, the rise in demand for novel drugs coupled with constant advancement in technology has boosted the market growth. In addition, major players in the market are working towards launching advanced instruments for bioprocessing. For instance, in October 2022, Univercells Technologies launched Scale-X™ cell collect module, with an aim of assisting the inoculation step for large-scale bioreactors leveraging the principles of automation and intensification.
Factors such as an increase in the incidence of infectious diseases coupled with rising demand of novel therapies, increasing adoption of bioprocessing instruments, and new product launches in the market are some of the prominent factors that are positively influencing the market growth globally.
Some of the major players operating in the market include Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher, Lonza, Thermo Fisher Scientific Inc., Siemens Healthineers, GE Healthcare, Eppendorf AG, Sartorious, and Advanced Instruments.
COVID-19 Impact
The recent covid-19 pandemic has disrupted the world and has brought a state of shock to the global economy. The global pandemic has impacted the healthcare industry and has transformed the way healthcare is delivered. The Bioprocess Technology Market has been significantly affected during these times owing to the delay in elective surgeries during the pandemic.
The global Bioprocess Technology Market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.
Based on type, the market is segmented into Consumables & Accessories, and Instruments. The Consumables & Accessories segment is sub-segmented into culture media, Reagents, and Others. The instruments are further sub-segmented into Bioprocess Analyzer, Blood Gas Analyzer, Osmometers, Cell Counter, Incubators, Bioreactors, and Others. The consumables & accessories category is expected to witness higher CAGR during the forecast period owing to the growing demand for cell culture bioprocessing in developing nations such as China, India, and Mexico, among others. Furthermore, The demand for bioprocess technology is being greatly fueled by biological studies on the effects of medications, the aging process, and the interactions between cells and disease-causing agents like bacteria and viruses, which is also positively influencing the growth of the market.
On the basis of application type, the market is categorized into Biopharmaceuticals, Specialty Products & Industrial Chemicals, and Environmental Management Aid. Among these, biopharmaceuticals to hold a significant share in the market in 2020. This is mainly due to the wide range of applications of bioprocessing in biopharmaceutical companies. The biopharmaceutical segment has been witnessing higher adoption of bioprocess technology, especially in the development of novel therapies including stem cell therapy, gene therapy, and immunotherapies. Moreover, the launch of new instruments including bioreactors, cell counters, bioprocess analyzer, etc. is expected to drive the industry at an exponential rate during the forecast period.
On the basis of end user, the market is segmented into Hospitals, Research Centers, Research / Academic Institutes. The research centers segment is to witness higher adoption of bioprocess technology during the forecast period. This is mainly due to the rising research and development in the pharmaceutical and biotechnology sector along with the increasing acquisition and partnerships in this sector. For instance,in July 2020, Sartorius AG, a leading provider of contract testing services to the biotechnology and biopharmaceutical industries, bought a majority share in CellGenix.
Have a Look at the Chapters https://univdatos.com/report/bioprocess-technology-market/
Bioprocess Technology Market Geographical Segmentation Includes:
North America (United States, Canada, and Rest of North America)
Europe (Germany, United Kingdom, Spain, Italy, France, and the Rest of Europe)
Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific)
Rest of the World
North America held a significant share of the global bioprocess technology market. This is mainly attributed to the increasing demand for personalized treatment such as cell therapy, gene therapy, etc. for the management of chronic disorders. Moreover, the increasing investments in biopharmaceutical companies and presence of global players in North America, also act as major factors that drive the growth of the industry. In addition, a wide variety of products are available in the North America market and many novel instruments also got approval in the region during the last few years. Increasing collaborations, partnerships, and acquisitions are also expected to drive the market in near future.
The major players targeting the market include
Hoffmann-La Roche Ltd.
Abbott Laboratories
Danaher
Lonza
Thermo Fisher Scientific Inc.
Siemens Healthineers
GE Healthcare
Eppendorf AG
Sartorious
Advanced Instruments
Competitive Landscape
The degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysts sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers, or acquisitions by leading companies in the Bioprocess Technology Market. The major players have been analyzed by using research methodologies for getting insight views on global competition.
Key questions resolved through this analytical market research report include:
What are the latest trends, new patterns, and technological advancements in the Bioprocess Technology Market?
Which factors are influencing the Bioprocess Technology Market over the forecast period?
What are the global challenges, threats, and risks in the Bioprocess Technology Market?
Which factors are propelling and restraining the Bioprocess Technology Market?
What are the demanding global regions of the Bioprocess Technology Market?
What will be the global market size in the upcoming years?
What are the crucial market acquisition strategies and policies applied by global companies?
We understand the requirement of different businesses, regions, and countries, we offer customized reports as per your requirements of business nature and geography. Please let us know If you have any custom needs.
About UnivDatos Market Insights (UMI)
Browse Other Related Research Reports from UnivDatos Market Insights
Biotechnology Market
Bioinformatics Market
Single-Use Bioprocessing Market
Bioprocess Containers Market
Pharmaceutical Packaging Market
Bioprocess Technology Market Report Coverage
Report Attribute
Details
Base year
2021
Forecast period
2022-2028
Growth momentum
Accelerate at a CAGR of over 5%
Market size 2020
USD 17.5 Billion
Regional analysis
North America, Europe, APAC, Rest of World
Major contributing region
North America to Dominate the Global Bioprocess Technology Market
Key countries covered
United States, Canada, Germany, United Kingdom, Spain, Italy, France, China, Japan, India
Companies profiled
Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher, Lonza, Thermo Fisher Scientific Inc., Siemens Healthineers, GE Healthcare, Eppendorf AG, Sartorious, and Advanced Instruments.
Report Scope
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Demand and Supply Side Analysis; Competitive Landscape; Company Profiling
Segments Covered
By Type; By Application Type; End-User; By Region/Country
 
About UnivDatos Market Insights
UnivDatos Market Insights (UMI) is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. Our research studies are spread across topics across the world, we cover markets in over 100 countries using smart research techniques and agile methodologies. We offer in-depth studies, detailed analysis, and customized reports that help shape winning business strategies for our clients.
Contact
UnivDatos Market Insights
Ankita Gupta
Director Operations
Ph: +91-7838604911
Email: Ankita.gupta@univdatos.com
Website: https://univdatos.com/
Logo: https://mma.prnewswire.com/media/1225049/UnivDatos_Logo.jpg
 
View original content:https://www.prnewswire.com/news-releases/bioprocess-technology-market-is-expected-to-display-a-steady-growth-of-10-8-due-to-the-rise-in-the-incidence-of-infectious-diseases–univdatos-market-insights-301686133.html
SOURCE UnivDatos Market Insights Pvt. Ltd.
Warren Buffett — the Oracle of Omaha — is widely regarded as one of the greatest investors of all time. Berkshire Hathaway Inc. (NYSE: BRK-A) has returned tens of thousands of percent over the years and consistently outperforms the market. Buffett purchased the company for just $8.3 million in 1965, and it’s now valued at nearly $700 billion, roughly a 10 million percent return. But one of Buffett’s top all-time picks and longest-held positions is one you might not expect. Berkshire Hathaway fir
Be greedy (and lazy) when others are fearful.
Plenty of things have gone wrong for Nio (NYSE: NIO) shareholders recently. Nio's American depositary shares were still higher by 6.4% as of 10:30 a.m. ET. This year was supposed to be somewhat of a breakout year for Nio.
With a history of decades-long investing success, billionaire Ken Griffin knows a thing or two about market behavior. Recently, the Citadel Investment Group Founder and CEO offered some of his thoughts on the state of the stock market and where the economy is heading. While Griffin believes inflation has already peaked, he thinks the Fed has yet to truly put the “genie back in the bottle.” He also thinks unemployment is about to rise and expects a recession will likely materialize “sometime in t
Concerns surrounding the growth of big tech do not apply to George Soros. The Federal Reserve's decision to aggressively raise interest rates to fight inflation, which is at a 40-year high, threatens to push the economy into a recession, many analysts say. This inflation, which is particularly impacting consumers, is a huge problem for the technology sector, because tech products and services are the first to suffer from spending cuts.
Tough times are coming. But you can still make money.
Yahoo Finance’s Alexandra Semenova discusses ARK Invest Founder Cathie Wood doubling down on bitcoin despite worries of an FTX contagion effect in crypto.
FTX collapsed. These players held the keys.
Here's the trading schedule for stocks and the bond market as investors prepare for Thanksgiving.
During a volatile week, shares of Carvana (NYSE: CVNA) were moving higher Wednesday morning, recovering from the sell-off that occurred Monday after management announced another round of layoffs and the stock got downgraded by analysts. A Securities and Exchange Commission filing Tuesday night showing that Carvana Chief Product Officer Daniel Gill bought 133,000 shares of the stock for roughly $1 million on Monday seems to be giving the used car e-commerce stock a boost. It's no secret that Carvana is in the midst of a liquidity crisis that could force it into bankruptcy.
In this article, we will discuss 12 best high-yield dividend stocks to buy now. You can skip our detailed analysis of high-dividend stocks and their performance over the years, and go directly to read 5 Best High-Yield Dividend Stocks To Buy Now. One of the main aspects of investing in dividend stocks is the sheer focus […]
A face of the regime of Sam Bankman-Fried, the founder of FTX, was revealed on November 22 during the firm's first hearing in Delaware bankruptcy court. The 30-year-old former trader was virtually considered an "emperor" among his employees: This is the image used by an FTX lawyer to describe what happened after Bankman-Fried filed for Chapter 11 bankruptcy on his crypto empire made up of FTX and Alameda Research. Everyone realized for the "first time the emperor had no clothes," James Bromley, co-head of the restructuring practice at law firm Sullivan & Cromwell, told Judge John Dorsey.
Some Twitter employees who chose to stay at the company as it transformed to "Twitter 2.0" are being shown the door.
AGNC Investment (NASDAQ: AGNC) was up as much as 4% in morning trading on Wednesday, the day before Thanksgiving. As of 2:30 p.m. ET, the stock price was up 2.8% to $9.77 per share. The major stock market indexes were all moving higher on Wednesday with the Nasdaq Composite leading the way, up about 96 points, or 1%, as of 2:30 p.m. ET.
Petrobras (PBR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Some of the world's most successful investors can't get enough of The Trade Desk, Shockwave Medical, and SoFi Technologies.
These supercharged income stocks, with yields ranging from 8.5% to 17.7%, were on billionaire money manager's buy lists during the third quarter.
Alibaba (BABA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intel Corp. (Nasdaq: INTC) said in a filing this week it would alter the CEO Pat Gelsinger's stock awards, changing the metrics for him to earn stock awards. The changes "increase the stock price performance hurdles for certain awards" and "provide even greater alignment with stockholders by lengthening the period during which stock price performance hurdles must be maintained." According to Intel's SEC filing Tuesday, Gelsinger's amended compensation raises the threshold for Gelsinger's performance-based awards.
High Tide Inc. ("High Tide" or the "Company") (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, announced today that according to new data recently released by the cannabis business publication, New Cannabis Ventures, the Company is now Canada's top revenue-generating cannabis company1.

source

Leave a Reply

Your email address will not be published. Required fields are marked *